What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “APG-157 is a first-in-class investigational drug product, formulated as 100 mg soft hydrogel pastille to dissolve in the mouth”In the company’s words, NCT07667296 on ClinicalTrials.gov
- Tested for
- Head and Neck Cancer (2 trials), Head and Neck (HNSCC), Oropharyngeal, Oral Cavity, Oral Cavity Carcinoma, Oropharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Squamous Cell Carcinoma of Oral Cavity and 3 more
- Main trialPhase 3
- “This Phase 3, multicenter, randomized, open-label study evaluates APG-157 in adults with newly diagnosed locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Two independently powered cohorts are enrolled based on treatment pathway. Cohort A evaluates APG-157 administered as neoadjuvant therapy before curative-intent surgery in participants with resectable oral cavity or oropharyngeal cancer who are medically ineligible for perioperative pembrolizumab. Cohort B evaluates APG-157 administered as induction therapy before definitive chemoradiotherapy and as maintenance therapy…”In the company’s words, NCT07667296 on ClinicalTrials.gov
Other drugs for Head and Neck Cancer
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- PenpulimabAkeso · Phase 3
Coming up3
- DecPhase 2 trial completes · ClinicalTrials.gov
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
- Dec 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | Dec 2031 | APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma | |
| Phase 2Active, not recruiting | Dec 2026 | Safety and Efficacy of APG-157 in Head and Neck Cancer | |
| Phase 1/2Active, not recruiting | 31 Dec 2026 | Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026